Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Saskatchewan Canadian Institutes of Health Research (CIHR) |
---|---|
Information provided by: | University of Saskatchewan |
ClinicalTrials.gov Identifier: | NCT00565240 |
We hypothesize that administration of an aromatase inhibitor (AI) and hormonal contraceptives (HC) in the mid-luteal phase of the menstrual cycle will result in atresia of the follicles in the extant wave and cause synchronous re-emergence of a new follicular wave. We anticipate that this will provide us with information to facilitate the development of a new method for ovarian synchronization; a safer, more effective ovulation induction therapy; a new method for emergency contraception; and a greater understanding of human folliculogenesis.
Condition | Intervention |
---|---|
Ovarian Follicle |
Drug: Marvelon Drug: Evra Patch Drug: Nuvaring Drug: Letrozole |
Study Type: | Interventional |
Study Design: | Health Services Research, Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | Mid-Luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971 |
Estimated Enrollment: | 53 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | September 2008 |
Arms | Assigned Interventions |
---|---|
Oral Contraceptive: Experimental |
Drug: Marvelon
oral contraceptive
|
Contraceptive Patch: Experimental |
Drug: Evra Patch
contraceptive patch
|
Contraceptive Ring: Experimental |
Drug: Nuvaring
contraceptive vaginal ring
|
Aromatase Inhibitors: Experimental |
Drug: Letrozole
Aromatase Inhibitors
|
Control: No Intervention |
Ages Eligible for Study: | 18 Years to 35 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
Contact: Terri Bloski | 306-966-7873 | bloski@erato.usask.ca |
Contact: Roger Pierson | 306-655-1000 | pierson@erato.usask.ca |
Canada, Saskatchewan | |
Royal University Hospital | Recruiting |
Saskatoon, Saskatchewan, Canada, S7N 0W8 | |
Principal Investigator: Roger A Pierson | |
Sub-Investigator: Femi Olatunbosun |
Principal Investigator: | Roger A Pierson | University of Saskatchewan |
Study ID Numbers: | WHIRL-07-2971 |
Study First Received: | November 27, 2007 |
Last Updated: | November 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00565240 |
Health Authority: | United States: Institutional Review Board; Canada: Health Canada |
ovarian synchronization folliculogenesis |
Ortho Evra Letrozole |